Vical Inc (VICL) 1.20 $VICL
HSV-2 Vaccine: Pharmaceutical Giant and Biotech Firm Join Forces; CBCD Commends Sanofi Pasteur (SNY) and Immune Design (IMDZ)
PRWeb - Tue Oct 21, 11:02PM CDT
"Infected with HSV-2? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
VICL: 1.20 (+0.01), IMDZ: 26.11 (+2.75), GSK: 43.63 (+0.02)
Global Gene Therapy Market & Pipeline Insight Report 2014 - Analysis of 315 Drug therapy Pipelines for the $500 Million Market
M2 - Fri Oct 17, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2nk3sv/global_gene) has announced the addition of the "Global Gene Therapy Market & Pipeline Insight" report to their offering. The global market opportunity for gene therapy is expected to reach USD 500 million by 2020 There have been significant advancements in the area of gene therapy in terms of research of new drugs. Over the past 20 years, the gene therapy market has witnessed significant advances ranging from the stage of conception, to the current stage of clinical trials for various disease conditions. When compared to other conventional methods such as radiotherapy and chemotherapy, gene therapy enjoys a clear advantage mainly because this therapy does not inhibit the immune system. Also, there has been an increased use of innovative technologies, which has led to an expansion of the scope of gene therapy worldwide. The growth of this market greatly depends on the regulatory approval of products which are currently in clinical trials. A major part of the gene therapy products for cancer and cardiovascular diseases are currently in Phase II and Phase III of clinical trials. Other factors impacting the gene therapy market are the cost of the treatment and the disease population under study. Additionally, funding and developments in research coupled with acceptance of gene therapy products to use in medicine are also expected to impact the market in the near future. Although the initial studies of gene therapy were conducted mostly on monogenetic diseases, the focus of the scientists rapidly shifted towards cancer. This increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for dominant share in the overall clinical trials being conducted. The major reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer. Global Gene Therapy Market & Pipeline Insight Market Highlight: - Gene Therapy Market Overview - Significance of Gene Therapy in Cancer Therapeutics - Current Applications of Gene Therapy to Cancer Treatment - Gene Therapy Market Dynamics: Drivers, Challenges & Future Outlook - FDA & AMA Guidelines for Gene Therapy - Gene Therapy Pipeline by Phase, Indications, Country & Company - Gene Therapy Pipeline: 246 Drugs - Marketed Gene Therapy: 2 (Gendicine & Rexin-G) - Cancer Gene Therapy Pipeline: 69 Drugs Key Topics Covered: 1. Introduction to Gene Therapy 2. Gene Therapy Classification 3. Mechanism of Gene Therapy 4. Global Gene Therapy Market Overview 5. Significance of Gene Therapy in Cancer Therapeutics 6. Current Applications of Gene Therapy to Cancer Treatment 7. Global Gene Therapy Market Dynamics 8. Gene Therapy Market Future Growth Outlook 9. EMA Guidelines for Gene Therapy 10. FDA Guidelines for Gene Therapy 11. Gene Therapy Pipeline by Phase, Indications, Country & Company 12. Marketed Gene Therapies by Indications, Country & Company 13. Suspended & Discontinued Gene Therapy in Pipeline 14. Competitive Landscape - Advantagene - BioCancell - Celgene - Epeius Biotechnologies - GenVec - Genethon - Introgen Therapeutics - MultiVir - Shenzhen SiBiono GeneTech - Vical - ZIOPHARM Oncology For more information visit http://www.researchandmarkets.com/research/2n...lobal_gene
VICL: 1.20 (+0.01), ZIOP: 2.55 (+0.08), CELGZ: 3.57 (-0.14)
Vical Incorporated (VICL) in Focus: Stock Soars 12% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 7:43AM CDT
Vical Incorporated (VICL) was a big mover last session, as the company saw its shares rise 12% on the day.
VICL: 1.20 (+0.01), EBS: 21.21 (-0.40), FCSC: 3.11 (+0.11), EPZM: 27.62 (+0.03)
Stock to Watch: Vical Up 15.1% (VICL)
Comtex SmarTrend(R) - Mon Oct 13, 11:37AM CDT
Vical (NASDAQ:VICL) is one of today's best performing low-priced stocks, up 15.1% to $1.24 on 8.1x average daily volume. Vical has traded 3.7 million shares thus far today, vs. average volume of 460,000 shares per day. The stock has outperformed the Dow (15.1% to the Dow's -0.3%) and outperformed the S&P 500 (15.1% to the S&P's -0.5%) during today's trading.
VICL: 1.20 (+0.01)
Vical Granted Six U.S. Patents for HSV-2 Vaccines
GlobeNewswire - Wed Oct 08, 5:36AM CDT
Vical Incorporated (Nasdaq:VICL) announced today the issuance of six U.S. patents that provide broad coverage of DNA vaccines for herpes simplex virus type 2 (HSV-2), containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant. These patents resulted from collaboration with the laboratories of leading HSV experts Drs. David Koelle and Lawrence Corey at the University of Washington under a multi-year NIH grant. The intellectual property is jointly owned by the University of Washington and Vical.
VICL: 1.20 (+0.01)
Global Gene Therapy Market Outlook 2018
M2 - Wed Sep 17, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bqlkd5/global_gene) has announced the addition of the "Global Gene Therapy Market Outlook 2018" report to their offering. Gene therapy is the treatment of a disease by replacing, altering, or supplementing a gene that is absent or abnormal and whose absence or abnormality is causing the disease. It has evolved as one of the most sought after research objectives for difficult to cure' diseases. The gene therapy market, presenting a few marketable products and being nascent in terms of revenue generation, holds tremendous growth potential. As per a new estimation carried out in our latest study, the global gene therapy industry has the potential to become a multi-million dollar industry by the end of 2018, as new products, especially those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth. Primarily, the gene therapy market is dominated by oncology applications with several companies and academic institutions focusing on novel and difficult to treat' cancers. Other therapeutic areas seeing developments in gene therapy include cardiac conditions, inherited blindness, genetic disorders and neurological diseases. An effective analysis of the key therapeutic areas has been included in the report. Also, a brief overview of the key geographies in the gene therapy market and the regulatory scenario governing the industry has been included to present a balanced outlook. Unlike other regions globally, the United States continues to have the maximum number of clinical trials in the gene therapy segment. This shows the country's potential to become a leader in gene therapy in the coming years. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Gene Therapy - An Introduction Classification of Gene Therapy Techniques Physical Methods of Gene Transfer - Electroporation - Hydrodynamic - Microinjection - Particle Bombardment - Ultrasound-mediated Transfection Vectors for Gene Therapy - Adenoviral Vectors - Adeno-associated Virus Vectors - Retroviral Vectors - Lentiviral Vectors - Plasmid DNA 4. Industry Trends and Drivers Industry Trends - Gene Silencing: Gaining Momentum - Advanced Therapies: Combining Gene Therapy and Stem Cell Technology - Immunodeficiency Syndromes: The Focus of Gene Therapy - Nanotechnology: Empowering Gene Therapy - Gene Therapy: A New Hope to Treat Blindness - Gene Therapy: Potential Cure for Cancer Market Drivers - Failure of Conventional Therapies to Treat Cancers - Entry of Gene Therapies in Developed Nations - Rising Incidence of Chronic and Life Threatening Diseases - Growing Interest of Venture Capital Firms 5. Market Restraints - High Cost of Treatment - Stringent Regulatory Laws & Safety Concerns - Pitfalls in Current Technique 6. Gene Therapy Market Outlook - Oncology - Infectious Diseases - Genetic Disorders - Cardiovascular Disorders - Diabetes Mellitus - Neurological Disorders 7. Gene Therapy Market - Regulatory Landscape 8. Advanced Gene Therapy Drugs - Collategene - Allovectin-7 - Generx - Glybera 9. Mergers and Acquisitions - Sangamo BioSciences to Acquire Gene Therapy Company Ceregene. - Baxter to Acquire Chatham Therapeutics - Bluebird Bio Acquired Privately Held Gene-Editing Company - Miltenyi Acquired Gene Therapy Assets from Lentigen - Dutch Player UniQure to Acquire InoCard GmbH for CHF Therapy. 10. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses, Key People) - Spark Therapeutics, LLC - ViroMed Co. Ltd. dba VM BioPharma - Advantagene Inc - Bluebird Bio - Sanofi - Genzyme - A Sanofi Company - Kolon Life Science - Vical Inc - Oxford BioMedica - Genethon For more information visit http://www.researchandmarkets.com/research/bq...lobal_gene
BLUE: 37.36 (+0.54), VICL: 1.20 (+0.01), SGMO: 10.52 (-0.18)
Vical to Present at the Rodman and Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Thu Sep 04, 5:35AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Wednesday, September 10, at 10:00 a.m. ET at the Rodman & Renshaw 16th Annual Global Investment Conference (New York, September 8 - 10). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 1.20 (+0.01)
Health Care Sector Stocks on our Radar -- Pacific Biosciences of California, Thermo Fisher Scientific, Lexicon Pharma, Vical, and Jazz Pharma
PR Newswire - Wed Aug 27, 7:50AM CDT
On Tuesday, August 26, 2014, the NASDAQ Composite ended at 4,570.64, up 0.29%, the Dow Jones Industrial Average finished the day 0.17% higher at 17,106.70, and the S&P 500 closed at 2,000.02, up 0.11%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 735.62, up 0.41%, and the index has advanced 7.97% in the last three months. Investor-Edge has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Thermo Fisher Scientific Inc. (NYSE: TMO), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Vical Inc. (NASDAQ: VICL), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free research on these five companies can be accessed at:
VICL: 1.20 (+0.01), PACB: 5.56 (unch), LXRX: 1.35 (+0.03), TMO: 118.22 (+3.89), JAZZ: 159.35 (+6.96)
Vical Reports Second Quarter 2014 Financial Results and Progress in Key Development Programs
GlobeNewswire - Thu Jul 31, 5:01AM CDT
Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and six months ended June 30, 2014. The net loss for the second quarter of 2014 was $4.0 million, or $0.05 per share, compared with a net loss of $9.9 million, or $0.11 per share, for the second quarter of 2013. Revenues for the second quarter of 2014 were $4.5 million, compared with revenues of $1.5 million for the second quarter of 2013, reflecting higher revenues from Astellas Pharma Inc. under an exclusive worldwide license of ASP0113, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
VICL: 1.20 (+0.01)
WEALTHMAKERS.COM Issues Bearish Research Reports on SLAB, TAP, TEAR, UAN, VICL, VSAT
M2 - Wed Jul 30, 9:44AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Silicon Laboratories Inc (NASDAQ:SLAB), Molson Coors Brewing Co (NYSE:TAP), Tearlab Corp (NASDAQ:TEAR), CVR Partners LP (NYSE:UAN), Vical Inc (NASDAQ:VICL), VIASAT, INC. (NASDAQ:VSAT)
VICL: 1.20 (+0.01), TEAR: 3.00 (-0.05), SLAB: 39.59 (+0.94), TAP: 71.84 (+1.61), UAN: 12.68 (+0.08), VSAT: 56.00 (+1.02)
Vical Announces News Release and Conference Call Schedule for Second Quarter 2014 Financial Results
GlobeNewswire - Thu Jul 24, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three and six months ended June 30, 2014, before the opening of trading on Thursday, July 31, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, July 31. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
VICL: 1.20 (+0.01)
Biotech Stocks Scanner -- Regeneron Pharma, BioCryst Pharma, Spectrum Pharma, Exact Sciences, and Vical Inc.
PR Newswire - Mon Jul 21, 8:10AM CDT
On Friday, July 18, 2014, the NASDAQ Composite ended at 4,432.15, up 1.57%, the Dow Jones Industrial Average finished the day 0.73% higher at 17,100.18, and the S&P 500 closed at 1,978.22, up 1.03%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 710.68, up 1.63%, and the index has advanced 6.63% in the previous three months. Investor-Edge has initiated coverage on the following equities: Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Exact Sciences Corporation (NASDAQ: EXAS), and Vical Inc. (NASDAQ: VICL). Free research on these five companies can be accessed at:
VICL: 1.20 (+0.01), BCRX: 11.37 (-0.23), EXAS: 24.22 (+0.36), SPPI: 7.62 (+0.13), REGN: 381.01 (+14.88)
5 Stocks Under $10 Set to Soar
at The Street - Fri Jul 18, 7:40AM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
VICL: 1.20 (+0.01), AVNW: 1.84 (-0.04), HPJ: 6.47 (-0.22), ASTI: 1.83 (+0.20), XGTI: 1.69 (+0.02), NIHD: 0.06 (-0.01)
XenoPort's XP23829 in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 3:52PM CDT
XenoPort, Inc. (XNPT) has commenced a phase II study on XP23829 for moderate-to-severe chronic plaque-type psoriasis.
VICL: 1.20 (+0.01), BIIB: 326.77 (+15.36), REGN: 381.01 (+14.88), XNPT: 6.35 (-0.04)
2014 Report of the International Therapeutic Vaccines Market - Forecasts to 2018
M2 - Wed Jun 18, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4s9wr9/global) has announced the addition of the "2014 Report of the International Therapeutic Vaccines Market - Forecasts to 2018" report to their offering. A therapeutic vaccine is a biological combination developed to improve immunity by inducing an attack against a diseased cell or tissue. This differs from prophylactic vaccines, which are administered to an individual with a disease in order to induce a defense mechanism. There are two approved cancer therapeutic vaccines on the market; Provenge and Oncophage. Additionally, a large number of therapeutic vaccines are under clinical development and are expected to be approved for use during the forecast period. The analysts forecast the Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Therapeutic Vaccine market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapeutic vaccines available in the market. The report, 2014 Report of the International Therapeutic Vaccines Market - Forecasts to 2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Therapeutic Vaccines market landscape and its growth prospects in the coming years. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Geographical Segmentation 08. Key Leading Countries 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Pipeline Analysis 17. Vendor Landscape 18. Key Vendor Analysis Companies Mentioned: - Agenus - Bavarian - Dendreon - GlaxoSmithKline - Novartis International - AFFiRiS - Argos Therapeutics - Celldex Therapeutics - CEL-SCI - Cytos Biotechnology - GlobeImmune - NewLink Genetics - NovaRx - Oncothyreon - TVAX Biomedical - TapImmune - Vical - Vaccinogen For more information visit http://www.researchandmarkets.com/research/4s9wr9/global
VICL: 1.20 (+0.01), ARGS: 9.11 (+0.11), CLDX: 14.74 (-0.41), NLNK: 34.50 (+3.06), GSK: 43.63 (+0.02), NVS: 88.61 (+0.71)
Vical to Present at the JMP Securities Annual Healthcare Conference
GlobeNewswire - Wed Jun 18, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Wednesday, June 25, at 12:30 p.m. ET at the JMP Securities Healthcare Conference 2014 (New York, June 24 - 25). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 1.20 (+0.01)
Analyst Scanner on Health Care Sector Equities -- Research on Vical, VCA Inc., TherapeuticsMD, and Theravance
PR Newswire - Mon Jun 16, 7:00AM CDT
The trading session on Friday, June 13, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,775.74, up 0.25% and the NASDAQ Composite closed at 4,310.65, up 0.30%. The S&P 500 finished the day 0.31% higher at 1,936.16. The gains were broad based as nine out of the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 688.44, down 0.02%, while the index has gained 2.46% in the previous one month. Investor-Edge has initiated coverage on the following equities: Vical Inc. (NASDAQ: VICL), VCA Inc. (NASDAQ: WOOF), TherapeuticsMD Inc. (NYSE MKT: TXMD) and Theravance Inc. (NASDAQ: THRX). Free technical research on VICL, WOOF, TXMD and THRX can be downloaded upon signing up at:
VICL: 1.20 (+0.01), TXMD: 4.15 (+0.11), THRX: 18.64 (+0.69), WOOF: 40.58 (+2.30)
Marrone Bio Innovations Hires VP of Technology Development
GlobeNewswire - Wed Mar 26, 8:00AM CDT
Marrone Bio Innovations, Inc. (MBI) (Nasdaq:MBII), a leading global provider of bio-based pest management and plant health products announced it has hired Amit Vasavada, Ph.D., as Vice President of Technology Development, a newly created position within the company. Dr. Vasavada brings 30 years of experience in industrial bioproducts, fermentation R&D and manufacturing, process engineering, and technology transfer to MBI. His broad commercial background includes positions with General Atomics, Vical Inc., Diversa Corporation, Monsanto (CP Kelco), and Chiron Corp.
VICL: 1.20 (+0.01), MBII: 3.06 (+0.45)
3 Stocks Under $10 Moving Higher
at The Street - Fri Mar 21, 5:18AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
VICL: 1.20 (+0.01), CJJD: 1.51 (-0.01), IFON: 1.62 (+0.01)
Why Vical (VICL) Might Be a Diamond in the Rough? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:46AM CDT
Vical has seen loss estimates narrowing over the past month and looks well positioned for a solid gain
VICL: 1.20 (+0.01)
HSV-2 Vaccine: Pharmaceutical Giant and Biotech Firm Join Forces; CBCD Commends Sanofi Pasteur (SNY) and Immune Design (IMDZ)
PRWeb - Tue Oct 21, 11:02PM CDT
"Infected with HSV-2? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD
VICL: 1.20 (+0.01), IMDZ: 26.11 (+2.75), GSK: 43.63 (+0.02)
Global Gene Therapy Market & Pipeline Insight Report 2014 - Analysis of 315 Drug therapy Pipelines for the $500 Million Market
M2 - Fri Oct 17, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2nk3sv/global_gene) has announced the addition of the "Global Gene Therapy Market & Pipeline Insight" report to their offering. The global market opportunity for gene therapy is expected to reach USD 500 million by 2020 There have been significant advancements in the area of gene therapy in terms of research of new drugs. Over the past 20 years, the gene therapy market has witnessed significant advances ranging from the stage of conception, to the current stage of clinical trials for various disease conditions. When compared to other conventional methods such as radiotherapy and chemotherapy, gene therapy enjoys a clear advantage mainly because this therapy does not inhibit the immune system. Also, there has been an increased use of innovative technologies, which has led to an expansion of the scope of gene therapy worldwide. The growth of this market greatly depends on the regulatory approval of products which are currently in clinical trials. A major part of the gene therapy products for cancer and cardiovascular diseases are currently in Phase II and Phase III of clinical trials. Other factors impacting the gene therapy market are the cost of the treatment and the disease population under study. Additionally, funding and developments in research coupled with acceptance of gene therapy products to use in medicine are also expected to impact the market in the near future. Although the initial studies of gene therapy were conducted mostly on monogenetic diseases, the focus of the scientists rapidly shifted towards cancer. This increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for dominant share in the overall clinical trials being conducted. The major reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer. Global Gene Therapy Market & Pipeline Insight Market Highlight: - Gene Therapy Market Overview - Significance of Gene Therapy in Cancer Therapeutics - Current Applications of Gene Therapy to Cancer Treatment - Gene Therapy Market Dynamics: Drivers, Challenges & Future Outlook - FDA & AMA Guidelines for Gene Therapy - Gene Therapy Pipeline by Phase, Indications, Country & Company - Gene Therapy Pipeline: 246 Drugs - Marketed Gene Therapy: 2 (Gendicine & Rexin-G) - Cancer Gene Therapy Pipeline: 69 Drugs Key Topics Covered: 1. Introduction to Gene Therapy 2. Gene Therapy Classification 3. Mechanism of Gene Therapy 4. Global Gene Therapy Market Overview 5. Significance of Gene Therapy in Cancer Therapeutics 6. Current Applications of Gene Therapy to Cancer Treatment 7. Global Gene Therapy Market Dynamics 8. Gene Therapy Market Future Growth Outlook 9. EMA Guidelines for Gene Therapy 10. FDA Guidelines for Gene Therapy 11. Gene Therapy Pipeline by Phase, Indications, Country & Company 12. Marketed Gene Therapies by Indications, Country & Company 13. Suspended & Discontinued Gene Therapy in Pipeline 14. Competitive Landscape - Advantagene - BioCancell - Celgene - Epeius Biotechnologies - GenVec - Genethon - Introgen Therapeutics - MultiVir - Shenzhen SiBiono GeneTech - Vical - ZIOPHARM Oncology For more information visit http://www.researchandmarkets.com/research/2n...lobal_gene
VICL: 1.20 (+0.01), ZIOP: 2.55 (+0.08), CELGZ: 3.57 (-0.14)
Vical Incorporated (VICL) in Focus: Stock Soars 12% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 7:43AM CDT
Vical Incorporated (VICL) was a big mover last session, as the company saw its shares rise 12% on the day.
VICL: 1.20 (+0.01), EBS: 21.21 (-0.40), FCSC: 3.11 (+0.11), EPZM: 27.62 (+0.03)
Stock to Watch: Vical Up 15.1% (VICL)
Comtex SmarTrend(R) - Mon Oct 13, 11:37AM CDT
Vical (NASDAQ:VICL) is one of today's best performing low-priced stocks, up 15.1% to $1.24 on 8.1x average daily volume. Vical has traded 3.7 million shares thus far today, vs. average volume of 460,000 shares per day. The stock has outperformed the Dow (15.1% to the Dow's -0.3%) and outperformed the S&P 500 (15.1% to the S&P's -0.5%) during today's trading.
VICL: 1.20 (+0.01)
Vical Granted Six U.S. Patents for HSV-2 Vaccines
GlobeNewswire - Wed Oct 08, 5:36AM CDT
Vical Incorporated (Nasdaq:VICL) announced today the issuance of six U.S. patents that provide broad coverage of DNA vaccines for herpes simplex virus type 2 (HSV-2), containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant. These patents resulted from collaboration with the laboratories of leading HSV experts Drs. David Koelle and Lawrence Corey at the University of Washington under a multi-year NIH grant. The intellectual property is jointly owned by the University of Washington and Vical.
VICL: 1.20 (+0.01)
Global Gene Therapy Market Outlook 2018
M2 - Wed Sep 17, 5:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bqlkd5/global_gene) has announced the addition of the "Global Gene Therapy Market Outlook 2018" report to their offering. Gene therapy is the treatment of a disease by replacing, altering, or supplementing a gene that is absent or abnormal and whose absence or abnormality is causing the disease. It has evolved as one of the most sought after research objectives for difficult to cure' diseases. The gene therapy market, presenting a few marketable products and being nascent in terms of revenue generation, holds tremendous growth potential. As per a new estimation carried out in our latest study, the global gene therapy industry has the potential to become a multi-million dollar industry by the end of 2018, as new products, especially those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth. Primarily, the gene therapy market is dominated by oncology applications with several companies and academic institutions focusing on novel and difficult to treat' cancers. Other therapeutic areas seeing developments in gene therapy include cardiac conditions, inherited blindness, genetic disorders and neurological diseases. An effective analysis of the key therapeutic areas has been included in the report. Also, a brief overview of the key geographies in the gene therapy market and the regulatory scenario governing the industry has been included to present a balanced outlook. Unlike other regions globally, the United States continues to have the maximum number of clinical trials in the gene therapy segment. This shows the country's potential to become a leader in gene therapy in the coming years. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Gene Therapy - An Introduction Classification of Gene Therapy Techniques Physical Methods of Gene Transfer - Electroporation - Hydrodynamic - Microinjection - Particle Bombardment - Ultrasound-mediated Transfection Vectors for Gene Therapy - Adenoviral Vectors - Adeno-associated Virus Vectors - Retroviral Vectors - Lentiviral Vectors - Plasmid DNA 4. Industry Trends and Drivers Industry Trends - Gene Silencing: Gaining Momentum - Advanced Therapies: Combining Gene Therapy and Stem Cell Technology - Immunodeficiency Syndromes: The Focus of Gene Therapy - Nanotechnology: Empowering Gene Therapy - Gene Therapy: A New Hope to Treat Blindness - Gene Therapy: Potential Cure for Cancer Market Drivers - Failure of Conventional Therapies to Treat Cancers - Entry of Gene Therapies in Developed Nations - Rising Incidence of Chronic and Life Threatening Diseases - Growing Interest of Venture Capital Firms 5. Market Restraints - High Cost of Treatment - Stringent Regulatory Laws & Safety Concerns - Pitfalls in Current Technique 6. Gene Therapy Market Outlook - Oncology - Infectious Diseases - Genetic Disorders - Cardiovascular Disorders - Diabetes Mellitus - Neurological Disorders 7. Gene Therapy Market - Regulatory Landscape 8. Advanced Gene Therapy Drugs - Collategene - Allovectin-7 - Generx - Glybera 9. Mergers and Acquisitions - Sangamo BioSciences to Acquire Gene Therapy Company Ceregene. - Baxter to Acquire Chatham Therapeutics - Bluebird Bio Acquired Privately Held Gene-Editing Company - Miltenyi Acquired Gene Therapy Assets from Lentigen - Dutch Player UniQure to Acquire InoCard GmbH for CHF Therapy. 10. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses, Key People) - Spark Therapeutics, LLC - ViroMed Co. Ltd. dba VM BioPharma - Advantagene Inc - Bluebird Bio - Sanofi - Genzyme - A Sanofi Company - Kolon Life Science - Vical Inc - Oxford BioMedica - Genethon For more information visit http://www.researchandmarkets.com/research/bq...lobal_gene
BLUE: 37.36 (+0.54), VICL: 1.20 (+0.01), SGMO: 10.52 (-0.18)
Vical to Present at the Rodman and Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Thu Sep 04, 5:35AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Wednesday, September 10, at 10:00 a.m. ET at the Rodman & Renshaw 16th Annual Global Investment Conference (New York, September 8 - 10). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 1.20 (+0.01)
Health Care Sector Stocks on our Radar -- Pacific Biosciences of California, Thermo Fisher Scientific, Lexicon Pharma, Vical, and Jazz Pharma
PR Newswire - Wed Aug 27, 7:50AM CDT
On Tuesday, August 26, 2014, the NASDAQ Composite ended at 4,570.64, up 0.29%, the Dow Jones Industrial Average finished the day 0.17% higher at 17,106.70, and the S&P 500 closed at 2,000.02, up 0.11%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 735.62, up 0.41%, and the index has advanced 7.97% in the last three months. Investor-Edge has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Thermo Fisher Scientific Inc. (NYSE: TMO), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), Vical Inc. (NASDAQ: VICL), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free research on these five companies can be accessed at:
VICL: 1.20 (+0.01), PACB: 5.56 (unch), LXRX: 1.35 (+0.03), TMO: 118.22 (+3.89), JAZZ: 159.35 (+6.96)
Vical Reports Second Quarter 2014 Financial Results and Progress in Key Development Programs
GlobeNewswire - Thu Jul 31, 5:01AM CDT
Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and six months ended June 30, 2014. The net loss for the second quarter of 2014 was $4.0 million, or $0.05 per share, compared with a net loss of $9.9 million, or $0.11 per share, for the second quarter of 2013. Revenues for the second quarter of 2014 were $4.5 million, compared with revenues of $1.5 million for the second quarter of 2013, reflecting higher revenues from Astellas Pharma Inc. under an exclusive worldwide license of ASP0113, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
VICL: 1.20 (+0.01)
WEALTHMAKERS.COM Issues Bearish Research Reports on SLAB, TAP, TEAR, UAN, VICL, VSAT
M2 - Wed Jul 30, 9:44AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Silicon Laboratories Inc (NASDAQ:SLAB), Molson Coors Brewing Co (NYSE:TAP), Tearlab Corp (NASDAQ:TEAR), CVR Partners LP (NYSE:UAN), Vical Inc (NASDAQ:VICL), VIASAT, INC. (NASDAQ:VSAT)
VICL: 1.20 (+0.01), TEAR: 3.00 (-0.05), SLAB: 39.59 (+0.94), TAP: 71.84 (+1.61), UAN: 12.68 (+0.08), VSAT: 56.00 (+1.02)
Vical Announces News Release and Conference Call Schedule for Second Quarter 2014 Financial Results
GlobeNewswire - Thu Jul 24, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three and six months ended June 30, 2014, before the opening of trading on Thursday, July 31, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, July 31. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
VICL: 1.20 (+0.01)
Biotech Stocks Scanner -- Regeneron Pharma, BioCryst Pharma, Spectrum Pharma, Exact Sciences, and Vical Inc.
PR Newswire - Mon Jul 21, 8:10AM CDT
On Friday, July 18, 2014, the NASDAQ Composite ended at 4,432.15, up 1.57%, the Dow Jones Industrial Average finished the day 0.73% higher at 17,100.18, and the S&P 500 closed at 1,978.22, up 1.03%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 710.68, up 1.63%, and the index has advanced 6.63% in the previous three months. Investor-Edge has initiated coverage on the following equities: Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Exact Sciences Corporation (NASDAQ: EXAS), and Vical Inc. (NASDAQ: VICL). Free research on these five companies can be accessed at:
VICL: 1.20 (+0.01), BCRX: 11.37 (-0.23), EXAS: 24.22 (+0.36), SPPI: 7.62 (+0.13), REGN: 381.01 (+14.88)
5 Stocks Under $10 Set to Soar
at The Street - Fri Jul 18, 7:40AM CDT
These under-$10 stocks look ready to break out and trade higher from current levels.
VICL: 1.20 (+0.01), AVNW: 1.84 (-0.04), HPJ: 6.47 (-0.22), ASTI: 1.83 (+0.20), XGTI: 1.69 (+0.02), NIHD: 0.06 (-0.01)
XenoPort's XP23829 in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 3:52PM CDT
XenoPort, Inc. (XNPT) has commenced a phase II study on XP23829 for moderate-to-severe chronic plaque-type psoriasis.
VICL: 1.20 (+0.01), BIIB: 326.77 (+15.36), REGN: 381.01 (+14.88), XNPT: 6.35 (-0.04)
2014 Report of the International Therapeutic Vaccines Market - Forecasts to 2018
M2 - Wed Jun 18, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4s9wr9/global) has announced the addition of the "2014 Report of the International Therapeutic Vaccines Market - Forecasts to 2018" report to their offering. A therapeutic vaccine is a biological combination developed to improve immunity by inducing an attack against a diseased cell or tissue. This differs from prophylactic vaccines, which are administered to an individual with a disease in order to induce a defense mechanism. There are two approved cancer therapeutic vaccines on the market; Provenge and Oncophage. Additionally, a large number of therapeutic vaccines are under clinical development and are expected to be approved for use during the forecast period. The analysts forecast the Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Therapeutic Vaccine market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapeutic vaccines available in the market. The report, 2014 Report of the International Therapeutic Vaccines Market - Forecasts to 2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Therapeutic Vaccines market landscape and its growth prospects in the coming years. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Geographical Segmentation 08. Key Leading Countries 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Pipeline Analysis 17. Vendor Landscape 18. Key Vendor Analysis Companies Mentioned: - Agenus - Bavarian - Dendreon - GlaxoSmithKline - Novartis International - AFFiRiS - Argos Therapeutics - Celldex Therapeutics - CEL-SCI - Cytos Biotechnology - GlobeImmune - NewLink Genetics - NovaRx - Oncothyreon - TVAX Biomedical - TapImmune - Vical - Vaccinogen For more information visit http://www.researchandmarkets.com/research/4s9wr9/global
VICL: 1.20 (+0.01), ARGS: 9.11 (+0.11), CLDX: 14.74 (-0.41), NLNK: 34.50 (+3.06), GSK: 43.63 (+0.02), NVS: 88.61 (+0.71)
Vical to Present at the JMP Securities Annual Healthcare Conference
GlobeNewswire - Wed Jun 18, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Wednesday, June 25, at 12:30 p.m. ET at the JMP Securities Healthcare Conference 2014 (New York, June 24 - 25). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
VICL: 1.20 (+0.01)
Analyst Scanner on Health Care Sector Equities -- Research on Vical, VCA Inc., TherapeuticsMD, and Theravance
PR Newswire - Mon Jun 16, 7:00AM CDT
The trading session on Friday, June 13, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,775.74, up 0.25% and the NASDAQ Composite closed at 4,310.65, up 0.30%. The S&P 500 finished the day 0.31% higher at 1,936.16. The gains were broad based as nine out of the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 688.44, down 0.02%, while the index has gained 2.46% in the previous one month. Investor-Edge has initiated coverage on the following equities: Vical Inc. (NASDAQ: VICL), VCA Inc. (NASDAQ: WOOF), TherapeuticsMD Inc. (NYSE MKT: TXMD) and Theravance Inc. (NASDAQ: THRX). Free technical research on VICL, WOOF, TXMD and THRX can be downloaded upon signing up at:
VICL: 1.20 (+0.01), TXMD: 4.15 (+0.11), THRX: 18.64 (+0.69), WOOF: 40.58 (+2.30)
Marrone Bio Innovations Hires VP of Technology Development
GlobeNewswire - Wed Mar 26, 8:00AM CDT
Marrone Bio Innovations, Inc. (MBI) (Nasdaq:MBII), a leading global provider of bio-based pest management and plant health products announced it has hired Amit Vasavada, Ph.D., as Vice President of Technology Development, a newly created position within the company. Dr. Vasavada brings 30 years of experience in industrial bioproducts, fermentation R&D and manufacturing, process engineering, and technology transfer to MBI. His broad commercial background includes positions with General Atomics, Vical Inc., Diversa Corporation, Monsanto (CP Kelco), and Chiron Corp.
VICL: 1.20 (+0.01), MBII: 3.06 (+0.45)
3 Stocks Under $10 Moving Higher
at The Street - Fri Mar 21, 5:18AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
VICL: 1.20 (+0.01), CJJD: 1.51 (-0.01), IFON: 1.62 (+0.01)
Why Vical (VICL) Might Be a Diamond in the Rough? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:46AM CDT
Vical has seen loss estimates narrowing over the past month and looks well positioned for a solid gain
VICL: 1.20 (+0.01)
